Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou .

Annals of the rheumatic diseases

Chatzidionysiou K, Samoli E, Sfikakis PP, Tektonidou MG.
PMID: 32753416
Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218444. Epub 2020 Aug 04.

No abstract available.

Cite
Chatzidionysiou K, Samoli E, Sfikakis PP, et al. Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218444.
Chatzidionysiou, K., Samoli, E., Sfikakis, P. P., & Tektonidou, M. G. (2020). Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218444
Chatzidionysiou, Katerina, et al. "Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218444
Chatzidionysiou K, Samoli E, Sfikakis PP, Tektonidou MG. Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218444. Epub 2020 Aug 04. PMID: 32753416.
Copy Download .nbib Format: NLM
Para-Clinical and Immunological Evaluation in Buerger's Disease as a Suspected Autoimmune Disease: Case Series.

Reports of biochemistry & molecular biology

Shapouri-Moghaddam A, Tavakkol Afshari SJ, Rahimi HR, Saeed Modaghegh MH, Mahmoudi M, Ehteshamfar SM.
PMID: 33969130
Rep Biochem Mol Biol. 2021 Jan;9(4):379-384. doi: 10.52547/rbmb.9.4.373.

BACKGROUND: Autoimmunity causes the loss of normal immune homeostasis and involves the presence of autoantibodies and inflammation. Thromboangiitis obliterans or Buerger's disease (BD) refers to a type of vascular obstructive syndrome, with tobacco exposure accounting for disease formation and...

Cite
Shapouri-Moghaddam A, Tavakkol Afshari SJ, Rahimi HR, et al. Para-Clinical and Immunological Evaluation in Buerger's Disease as a Suspected Autoimmune Disease: Case Series. Rep Biochem Mol Biol. 2021;9(4):379-384doi: 10.52547/rbmb.9.4.373.
Shapouri-Moghaddam, A., Tavakkol Afshari, S. J., Rahimi, H. R., Saeed Modaghegh, M. H., Mahmoudi, M., & Ehteshamfar, S. M. (2021). Para-Clinical and Immunological Evaluation in Buerger's Disease as a Suspected Autoimmune Disease: Case Series. Reports of biochemistry & molecular biology, 9(4), 379-384. https://doi.org/10.52547/rbmb.9.4.373
Shapouri-Moghaddam, Abbas, et al. "Para-Clinical and Immunological Evaluation in Buerger's Disease as a Suspected Autoimmune Disease: Case Series." Reports of biochemistry & molecular biology vol. 9,4 (2021): 379-384. doi: https://doi.org/10.52547/rbmb.9.4.373
Shapouri-Moghaddam A, Tavakkol Afshari SJ, Rahimi HR, Saeed Modaghegh MH, Mahmoudi M, Ehteshamfar SM. Para-Clinical and Immunological Evaluation in Buerger's Disease as a Suspected Autoimmune Disease: Case Series. Rep Biochem Mol Biol. 2021 Jan;9(4):379-384. doi: 10.52547/rbmb.9.4.373. PMID: 33969130; PMCID: PMC8068440.
Copy Download .nbib Format: NLM
Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women.

Obstetrics & gynecology science

Lee GS, Park JC, Rhee JH, Kim JI.
PMID: 27668201
Obstet Gynecol Sci. 2016 Sep;59(5):379-87. doi: 10.5468/ogs.2016.59.5.379. Epub 2016 Sep 13.

OBJECTIVE: The goal of this study was to evaluate the etiologies and clinical outcomes of Korean recurrent pregnancy loss (RPL) patients. And also, we investigated the differences between primary and secondary RPL patients, between two and three or more...

Cite
Lee GS, Park JC, Rhee JH, et al. Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women. Obstet Gynecol Sci. 2016;59(5):379-87doi: 10.5468/ogs.2016.59.5.379.
Lee, G. S., Park, J. C., Rhee, J. H., & Kim, J. I. (2016). Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women. Obstetrics & gynecology science, 59(5), 379-87. https://doi.org/10.5468/ogs.2016.59.5.379
Lee, Gi Su, et al. "Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women." Obstetrics & gynecology science vol. 59,5 (2016): 379-87. doi: https://doi.org/10.5468/ogs.2016.59.5.379
Lee GS, Park JC, Rhee JH, Kim JI. Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women. Obstet Gynecol Sci. 2016 Sep;59(5):379-87. doi: 10.5468/ogs.2016.59.5.379. Epub 2016 Sep 13. PMID: 27668201; PMCID: PMC5028645.
Copy Download .nbib Format: NLM
Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou .

Annals of the rheumatic diseases

Bettiol A, Pregnolato F, Sciascia S, Emmi G, Prisco D, Meroni PL.
PMID: 32753414
Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218377. Epub 2020 Aug 04.

No abstract available.

Cite
Bettiol A, Pregnolato F, Sciascia S, et al. Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218377.
Bettiol, A., Pregnolato, F., Sciascia, S., Emmi, G., Prisco, D., & Meroni, P. L. (2020). Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218377
Bettiol, Alessandra, et al. "Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218377
Bettiol A, Pregnolato F, Sciascia S, Emmi G, Prisco D, Meroni PL. Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218377. Epub 2020 Aug 04. PMID: 32753414.
Copy Download .nbib Format: NLM
Predictors of peripheral arterial disease in SLE change with patient's age.

Lupus science & medicine

Erdozain JG, Villar I, Nieto J, Ruiz-Arruza I, Ruiz-Irastorza G.
PMID: 28123770
Lupus Sci Med. 2017 Jan 12;4(1):e000190. doi: 10.1136/lupus-2016-000190. eCollection 2017.

OBJECTIVE: To analyse the differential influence of risk factors of peripheral artery disease (PAD) according to age in patients with SLE.METHODS: 216 patients from the Lupus-Cruces cohort were divided in three age groups: ≤34 years, 35-49 years and ≥50...

Cite
Erdozain JG, Villar I, Nieto J, et al. Predictors of peripheral arterial disease in SLE change with patient's age. Lupus Sci Med. 2017;4(1):e000190doi: 10.1136/lupus-2016-000190.
Erdozain, J. G., Villar, I., Nieto, J., Ruiz-Arruza, I., & Ruiz-Irastorza, G. (2017). Predictors of peripheral arterial disease in SLE change with patient's age. Lupus science & medicine, 4(1), e000190. https://doi.org/10.1136/lupus-2016-000190
Erdozain, Jose-Gabriel, et al. "Predictors of peripheral arterial disease in SLE change with patient's age." Lupus science & medicine vol. 4,1 (2017): e000190. doi: https://doi.org/10.1136/lupus-2016-000190
Erdozain JG, Villar I, Nieto J, Ruiz-Arruza I, Ruiz-Irastorza G. Predictors of peripheral arterial disease in SLE change with patient's age. Lupus Sci Med. 2017 Jan 12;4(1):e000190. doi: 10.1136/lupus-2016-000190. eCollection 2017. PMID: 28123770; PMCID: PMC5255560.
Copy Download .nbib Format: NLM
Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome.

Tuberculosis and respiratory diseases

Na YS, Jang S, Hong S, Oh YM, Lee SD, Lee JS.
PMID: 30574689
Tuberc Respir Dis (Seoul). 2019 Jan;82(1):53-61. doi: 10.4046/trd.2018.0045.

BACKGROUND: Antiphospholipid antibody syndrome (APS), an important cause of acquired thrombophilia, is diagnosed when vascular thrombosis or pregnancy morbidity occurs with persistently positive antiphospholipid antibodies (aPL). APS is a risk factor for unprovoked recurrence of pulmonary embolism (PE). Performing...

Cite
Na YS, Jang S, Hong S, et al. Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome. Tuberc Respir Dis (Seoul). 2019;82(1):53-61doi: 10.4046/trd.2018.0045.
Na, Y. S., Jang, S., Hong, S., Oh, Y. M., Lee, S. D., & Lee, J. S. (2019). Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome. Tuberculosis and respiratory diseases, 82(1), 53-61. https://doi.org/10.4046/trd.2018.0045
Na, Yong Sub, et al. "Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome." Tuberculosis and respiratory diseases vol. 82,1 (2019): 53-61. doi: https://doi.org/10.4046/trd.2018.0045
Na YS, Jang S, Hong S, Oh YM, Lee SD, Lee JS. Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome. Tuberc Respir Dis (Seoul). 2019 Jan;82(1):53-61. doi: 10.4046/trd.2018.0045. PMID: 30574689; PMCID: PMC6304333.
Copy Download .nbib Format: NLM
Effects of thrombophilia and antithrombotic therapy on embryonic chromosomal aberration rates in patients with recurrent pregnancy loss.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

Ouchi N, Takeshita T, Kasano S, Yokote R, Yonezawa M, Kurashina R, Ichikawa T, Kawabata I, Kuwabara Y.
PMID: 33867424
J Nippon Med Sch. 2021 Apr 19; doi: 10.1272/jnms.JNMS.2022_89-103. Epub 2021 Apr 19.

BACKGROUND: Miscarriage occurs in 10-15% of pregnancies and recurrent pregnancy loss (RPL) occurs in 1% of couples hoping for a child. Various risk factors, such as thrombophilia, uterine malformation, and embryonic chromosomal aberration cause RPL. We hypothesized that antithrombotic...

Cite
Ouchi N, Takeshita T, Kasano S, et al. Effects of thrombophilia and antithrombotic therapy on embryonic chromosomal aberration rates in patients with recurrent pregnancy loss. J Nippon Med Sch. 2021;doi: 10.1272/jnms.JNMS.2022_89-103.
Ouchi, N., Takeshita, T., Kasano, S., Yokote, R., Yonezawa, M., Kurashina, R., Ichikawa, T., Kawabata, I., & Kuwabara, Y. (2021). Effects of thrombophilia and antithrombotic therapy on embryonic chromosomal aberration rates in patients with recurrent pregnancy loss. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, . https://doi.org/10.1272/jnms.JNMS.2022_89-103
Ouchi, Nozomi, et al. "Effects of thrombophilia and antithrombotic therapy on embryonic chromosomal aberration rates in patients with recurrent pregnancy loss." Journal of Nippon Medical School = Nippon Ika Daigaku zasshi vol. (2021). doi: https://doi.org/10.1272/jnms.JNMS.2022_89-103
Ouchi N, Takeshita T, Kasano S, Yokote R, Yonezawa M, Kurashina R, Ichikawa T, Kawabata I, Kuwabara Y. Effects of thrombophilia and antithrombotic therapy on embryonic chromosomal aberration rates in patients with recurrent pregnancy loss. J Nippon Med Sch. 2021 Apr 19; doi: 10.1272/jnms.JNMS.2022_89-103. Epub 2021 Apr 19. PMID: 33867424.
Copy Download .nbib Format: NLM
Current status and role of antiphospholipid antibody testing in cryptogenic stroke.

European journal of neurology

Yang W, Kang MK, Ha SY, Kang DW, Bae J, Lee EJ, Jeong HY, Kim JM, Jung KH, Lee SH.
PMID: 34800314
Eur J Neurol. 2021 Nov 20; doi: 10.1111/ene.15191. Epub 2021 Nov 20.

BACKGROUND AND PURPOSE: Although it is not recognized as essential to test for antiphospholipid antibody (aPL) in stroke of unknown cause, aPL-related stroke may account for a considerable number of cryptogenic strokes. We aimed to assess the current status...

Cite
Yang W, Kang MK, Ha SY, et al. Current status and role of antiphospholipid antibody testing in cryptogenic stroke. Eur J Neurol. 2021;doi: 10.1111/ene.15191.
Yang, W., Kang, M. K., Ha, S. Y., Kang, D. W., Bae, J., Lee, E. J., Jeong, H. Y., Kim, J. M., Jung, K. H., & Lee, S. H. (2021). Current status and role of antiphospholipid antibody testing in cryptogenic stroke. European journal of neurology, . https://doi.org/10.1111/ene.15191
Yang, Wookjin, et al. "Current status and role of antiphospholipid antibody testing in cryptogenic stroke." European journal of neurology vol. (2021). doi: https://doi.org/10.1111/ene.15191
Yang W, Kang MK, Ha SY, Kang DW, Bae J, Lee EJ, Jeong HY, Kim JM, Jung KH, Lee SH. Current status and role of antiphospholipid antibody testing in cryptogenic stroke. Eur J Neurol. 2021 Nov 20; doi: 10.1111/ene.15191. Epub 2021 Nov 20. PMID: 34800314.
Copy Download .nbib Format: NLM
Pregnancy Management in Women with Antiphospholidic Syndrome.

Maedica

Radu A, Dudu SC, Ciobanu A, Peltecu G, Iancu G, Botezatu R, Gica N, Panaitescu AM.
PMID: 31523297
Maedica (Bucur). 2019 Jun;14(2):148-160. doi: 10.26574/maedica.2019.14.2.148.

The antiphospholipid syndrome (APS or Hughes Syndrome) is a systemic autoimmune disease characterised by the presence of specific and persistent circulating antiphospholipid antibodies (APL) and the subsequent morbidities they cause, including pregnancy complications and thrombosis. The three main antiphospholipid...

Cite
Radu A, Dudu SC, Ciobanu A, et al. Pregnancy Management in Women with Antiphospholidic Syndrome. Maedica (Bucur). 2019;14(2):148-160doi: 10.26574/maedica.2019.14.2.148.
Radu, A., Dudu, S. C., Ciobanu, A., Peltecu, G., Iancu, G., Botezatu, R., Gica, N., & Panaitescu, A. M. (2019). Pregnancy Management in Women with Antiphospholidic Syndrome. Maedica, 14(2), 148-160. https://doi.org/10.26574/maedica.2019.14.2.148
Radu, Andreea, et al. "Pregnancy Management in Women with Antiphospholidic Syndrome." Maedica vol. 14,2 (2019): 148-160. doi: https://doi.org/10.26574/maedica.2019.14.2.148
Radu A, Dudu SC, Ciobanu A, Peltecu G, Iancu G, Botezatu R, Gica N, Panaitescu AM. Pregnancy Management in Women with Antiphospholidic Syndrome. Maedica (Bucur). 2019 Jun;14(2):148-160. doi: 10.26574/maedica.2019.14.2.148. PMID: 31523297; PMCID: PMC6709396.
Copy Download .nbib Format: NLM
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.

Journal of thrombosis and haemostasis : JTH

Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A.
PMID: 29978552
J Thromb Haemost. 2018 Jun 07; doi: 10.1111/jth.14192. Epub 2018 Jun 07.

Background The McMaster RARE-Bestpractices project group selected the catastrophic antiphospholipid syndrome (CAPS) for a pilot exercise in guideline development for a rare disease. Objectives The objectives of this exercise were to provide a proof of principle that guidelines can...

Cite
Legault K, Schunemann H, Hillis C, et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018;doi: 10.1111/jth.14192.
Legault, K., Schunemann, H., Hillis, C., Yeung, C., Akl, E. A., Carrier, M., Cervera, R., Crowther, M., Dentali, F., Erkan, D., Espinosa, G., Khamashta, M., Meerpohl, J. J., Moffat, K., O'Brien, S., Pengo, V., Rand, J. H., Rodriguez Pinto, I., Thom, L., & Iorio, A. (2018). McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. Journal of thrombosis and haemostasis : JTH, . https://doi.org/10.1111/jth.14192
Legault, K, et al. "McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome." Journal of thrombosis and haemostasis : JTH vol. (2018). doi: https://doi.org/10.1111/jth.14192
Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018 Jun 07; doi: 10.1111/jth.14192. Epub 2018 Jun 07. PMID: 29978552.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries